Trinity Biotech shares surge 14.02% premarket after securing regulatory clearances for expanded rollout of high-capacity HbA1c column system in key markets.

Trinity Biotech surged 14.02% in premarket trading following the announcement of regulatory clearances for its next-generation high-capacity HbA1c column system, enabling expanded global rollout to over 10 countries, including the U.S. The upgraded system for the Premier Hb9210 analyzer offers four times the testing capacity of the previous version, reduces downtime, and enhances operational efficiency, positioning the company to capture growth in the $2B+ HbA1c market projected to exceed $3.5B by 2030. The CEO highlighted the strategic value of the rollout in key markets, emphasizing automation, recurring revenue potential, and strengthened competitive positioning in diabetes care.